Cancer Australia has announced the first Australian study to track how patients with cancer respond to the covid vaccine.
Cancer Australia has announced the first Australian study to track how patients with cancer respond to the covid vaccine.
The SerOzNET study, announced in the last week of June, will investigate the safety and efficacy of covid vaccines in patients with cancer.
“People with cancer were largely excluded from the initial international clinical trials for the COVID-19 vaccines, but we know that they are more vulnerable to COVID-19 infection and are at increased risk of more severe infection,” said Professor Dorothy Keefe, the CEO of Cancer Australia.
“The SerOzNET study presents a critical opportunity to contribute to the science in relation to COVID-19 vaccination of cancer patients.
“The study may also be able to give us important insights, including potentially how different therapies impact on vaccine response; how patients with different types of cancers, including blood cancers, respond to the vaccines; and the impact of timing of the vaccine for patients on cancer treatments.”
The SerOzNET study is based on a study protocol from the US National Cancer Institute Serological Sciences Network for COVID-19 (SeroNet).
Monash Health in Victoria is the lead site for the clinical study and Professor Eva Segelov is the principal investigator.
